AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20881473 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, multicomponent HIV and reproductive health intervention.
Number of subjects: 4684
Study 20881473 — intervention group
Group type: COMPARATOR
Intervention: Control group (deferred implementation of the intervention).
Number of subjects: 4684
Study 19100928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bladder catheterization (Group IC; n = 109)
Number of subjects: 209
Study 19100928 — intervention group
Group type: COMPARATOR
Intervention: Continuous bladder catheterization (Group CC; n = 100)
Number of subjects: 209
Study 16337368 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 0
Study 16337368 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 0
Study 12769155 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% polyvinylpyrrolidone (PVP) solution
Number of subjects: 39
Study 12769155 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution
Number of subjects: 39
Study 11081985 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized extract (SHA-10) of Andrographis paniculata fixed combination (Kan jang) taken three times daily for a minimum of 3 days and a maximum of 8 days (pilot study) or for exactly three days (phase III study)
Number of subjects: 225
Study 11081985 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized extract (SHA-10) of Andrographis paniculata fixed combination (Kan jang)
Number of subjects: 225
Study 11081985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 9352698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 126
Study 9352698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.6 mg
Number of subjects: 126
Study 9352698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg
Number of subjects: 126
Study 9352698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 9352698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (all doses)
Number of subjects: 126
Study 9352698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 126
Study 8463026 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (WALK) group exercised 5 d.wk-1 for 30-40 min per session at 60.0 +/- 1.9% heart rate reserve
Number of subjects: 30
Study 8463026 — intervention group
Group type: COMPARATOR
Intervention: Calisthenics control (CAL) group engaged in mild musculoskeletal exercise
Number of subjects: 30
Study 4037540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally)
Number of subjects: 8
Study 4037540 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg bolus followed by continuous infusion)
Number of subjects: 8
Study 4037540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29677007 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (unblinded)
Number of subjects: 77
Study 29677007 — intervention group
Group type: COMPARATOR
Intervention: Intermittent glucose monitoring (blinded)
Number of subjects: 77
Study 26995374 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 25 to 100 mg BID
Number of subjects: 248
Study 26995374 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 248
Study 24438128 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley manoeuvre
Number of subjects: 44
Study 24438128 — intervention group
Group type: COMPARATOR
Intervention: Sham manoeuvre
Number of subjects: 44
Study 22357892 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted cognitive rehabilitation of attention and information processing and executive functions (n = 10)
Number of subjects: 20
Study 22357892 — intervention group
Group type: COMPARATOR
Intervention: Control group without cognitive rehabilitation (n = 10)
Number of subjects: 20
Study 19118910 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 24
Study 19118910 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 24
Study 17727860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg/day
Number of subjects: 44
Study 17727860 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/day
Number of subjects: 44
Study 17727860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (overall)
Number of subjects: 44
Study 17727860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (in patients without portacaval shunt or plasmapheresis)
Number of subjects: 44
Study 17727860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Atorvastatin (crossover treatment)
Number of subjects: 44
Study 15851919 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rgp120 vaccine
Number of subjects: 5403
Study 14646367 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure patients with heavy proteinuria
Number of subjects: 20
Study 10799382 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg) with low-fat spread
Number of subjects: 15
Study 10799382 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg) with high-fat spread
Number of subjects: 15
Study 10799382 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha- plus beta-carotene (8 mg) with low-fat spread
Number of subjects: 15
Study 10799382 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha- plus beta-carotene (8 mg) with high-fat spread
Number of subjects: 15
Study 10799382 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein esters (8 mg lutein) with low-fat spread
Number of subjects: 15
Study 10799382 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein esters (8 mg lutein) with high-fat spread
Number of subjects: 15
Study 10799382 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low-fat spread
Number of subjects: 15
Study 10799382 — intervention group
Group type: COMPARATOR
Intervention: Placebo with high-fat spread
Number of subjects: 15
Study 8830946 — intervention group
Group type: EXPERIMENTAL
Intervention: High +Gz forces during aerial combat maneuvering for 40 min
Number of subjects: 20
Study 8830946 — intervention group
Group type: COMPARATOR
Intervention: Recumbent rest before flights
Number of subjects: 20
Study 8830946 — intervention group
Group type: COMPARATOR
Intervention: Sitting in an aircraft on the ground
Number of subjects: 20
Study 1601799 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary contractions at 10, 25, 50, 75, 85, and 100% of maximal voluntary contraction (MVC) force
Number of subjects: 0
Study 1601799 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated contractions produced by supramaximal electrical stimulation of the ulnar nerve at frequencies of 10, 20, 30, 50, 70, and 100 Hz
Number of subjects: 0
Study 3904886 — intervention group
Group type: EXPERIMENTAL
Intervention: Indalpine 150 mg per day
Number of subjects: 65
Study 3904886 — intervention group
Group type: COMPARATOR
Intervention: Mianserin 60 mg per day
Number of subjects: 65
Study 30105510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag 2 mg once daily for 7 days
Number of subjects: 61
Study 30105510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag 3 mg once daily for 7 days
Number of subjects: 61
Study 30105510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag 4 mg once daily for 7 days
Number of subjects: 61
Study 30105510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30415782 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceptional human experiences (EHEs) reported by scientists and engineers
Number of subjects: 999
Study 30415782 — intervention group
Group type: COMPARATOR
Intervention: Exceptional human experiences (EHEs) reported by the general population
Number of subjects: 999
Study 30415782 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceptional human experiences (EHEs) reported by enthusiasts
Number of subjects: 999
Study 30415782 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranormal belief levels
Number of subjects: 999
Study 30415782 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between belief and experience
Number of subjects: 999
Study 26704258 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Cortical Stimulation (CS) combined with intensive language therapy (3 hours a day for 6 weeks)
Number of subjects: 8
Study 26704258 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Cortical Stimulation (CS) combined with intensive language therapy
Number of subjects: 8
Study 26704258 — intervention group
Group type: COMPARATOR
Intervention: Epidural Cortical Stimulation (CS)
Number of subjects: 8
Study 25306677 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC applied during sevoflurane anesthesia (RIPCsevo)
Number of subjects: 48
Study 25306677 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 48
Study 25306677 — intervention group
Group type: COMPARATOR
Intervention: RIPC applied during propofol anesthesia (RIPCprop)
Number of subjects: 48
Study 22309641 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational secondary prevention program 'En nu ik...!'
Number of subjects: 140
Study 22309641 — intervention group
Group type: COMPARATOR
Intervention: Control program offering positive attention, recreation, distraction, warmth, and empathy
Number of subjects: 140
Study 20103451 — intervention group
Group type: EXPERIMENTAL
Intervention: Discount coupon for oral contraceptive pills (OCPs)
Number of subjects: 0
Study 20103451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coupon)
Number of subjects: 0
Study 17907147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program integrating exercise, self-management, and active coping strategies (ESCAPE-knee pain)
Number of subjects: 418
Study 17907147 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual rehabilitation
Number of subjects: 418
Study 17907147 — intervention group
Group type: EXPERIMENTAL
Intervention: Group rehabilitation
Number of subjects: 418
Study 17907147 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 418
Study 16256766 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract for Change + Food Guide Pyramid lessons
Number of subjects: 38
Study 16256766 — intervention group
Group type: COMPARATOR
Intervention: Food Guide Pyramid lessons
Number of subjects: 38
Study 11152898 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (800 mg) and topical benzocaine (20%)
Number of subjects: 99
Study 11152898 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo and topical benzocaine (20%)
Number of subjects: 99
Study 11152898 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (800 mg) and topical placebo
Number of subjects: 99
Study 11152898 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo and topical placebo
Number of subjects: 99
Study 9547774 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 30
Study 9547774 — intervention group
Group type: COMPARATOR
Intervention: Local peribulbar block
Number of subjects: 30
Study 7981922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0
Study 7981922 — intervention group
Group type: COMPARATOR
Intervention: Investigated drugs
Number of subjects: 0
Study 3597241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 ppm O3
Number of subjects: 40
Study 3597241 — intervention group
Group type: COMPARATOR
Intervention: 0.60 ppm NO2
Number of subjects: 40
Study 3597241 — intervention group
Group type: COMPARATOR
Intervention: 0.60 ppm NO2 plus 0.30 ppm O3
Number of subjects: 40
Study 31494028 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine Parent/Nurse Controlled Analgesia (PNCA)
Number of subjects: 25
Study 31494028 — intervention group
Group type: COMPARATOR
Intervention: Continuous Opioid Infusion (COI)
Number of subjects: 25
Study 29909156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trivalent influenza vaccine
Number of subjects: 9300
Study 29909156 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine
Number of subjects: 9300
Study 27563320 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotomy position
Number of subjects: 96
Study 27563320 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting position
Number of subjects: 96
Study 27563320 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 96
Study 27563320 — intervention group
Group type: EXPERIMENTAL
Intervention: All three positions
Number of subjects: 96
Study 24748338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg tablets, twice per week for 12 weeks)
Number of subjects: 140
Study 24748338 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist (decapeptyl, 3.75 mg subcutaneous, single injection, once a month for 3 months)
Number of subjects: 140
Study 23735004 — intervention group
Group type: EXPERIMENTAL
Intervention: diet and orlistat
Number of subjects: 67
Study 23735004 — intervention group
Group type: EXPERIMENTAL
Intervention: diet, orlistat and exercise
Number of subjects: 67
Study 23735004 — intervention group
Group type: COMPARATOR
Intervention: diet alone
Number of subjects: 67
Study 21256927 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 13
Study 21256927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19712544 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging reminder
Number of subjects: 931
Study 19712544 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder
Number of subjects: 931
Study 19712544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 931
Study 17133193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention in addition to standard care
Number of subjects: 0
Study 17133193 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 15334276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox (Loprox) gel
Number of subjects: 0
Study 11041471 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrow-Trerotola percutaneous thrombolytic device (PTD)
Number of subjects: 10
Study 9024265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical hPTH-(1-34) (800 U)
Number of subjects: 30
Study 9024265 — intervention group
Group type: COMPARATOR
Intervention: Cyclical hPTH-(1-34) + sequential calcitonin (75 U/day)
Number of subjects: 30
Study 8111174 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion (study group)
Number of subjects: 30
Study 8111174 — intervention group
Group type: COMPARATOR
Intervention: No exchange transfusion (control group)
Number of subjects: 30
Study 6696209 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated conjunctival provocation tests (CPT)
Number of subjects: 20
Study 30712954 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 61
Study 30712954 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 61
Study 30712954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ADA and AZA
Number of subjects: 61
Study 30712954 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without endoscopic recurrence
Number of subjects: 61
Study 30712954 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI score correlation
Number of subjects: 61
Study 29940266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT, n=14)
Number of subjects: 51
Study 29940266 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising Control (CON, n=12)
Number of subjects: 51
Study 29940266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined High-Intensity Interval and Resistance Training (HIIT+RT, n=13)
Number of subjects: 51
Study 29940266 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT, n=12)
Number of subjects: 51
Study 27394381 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine low dose aspirin (LDA) 75 mg once daily from first trimester until 36-week gestation
Number of subjects: 0
Study 27394381 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 0
Study 27394381 — intervention group
Group type: EXPERIMENTAL
Intervention: LDA based on a positive first trimester screening test
Number of subjects: 0
Study 24495314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin/metformin sustained-release fixed-dose combination tablet (25/500 mg x 2 tablets) in high-fat fed state
Number of subjects: 24
Study 24495314 — intervention group
Group type: COMPARATOR
Intervention: Gemigliptin/metformin sustained-release fixed-dose combination tablet (25/500 mg x 2 tablets) in fasted state
Number of subjects: 24
Study 20456259 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis (Group A)
Number of subjects: 41
Study 20456259 — intervention group
Group type: COMPARATOR
Intervention: No anterior chamber paracentesis (Group B)
Number of subjects: 41
Study 20972900 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT combined with CRP
Number of subjects: 3
Study 20972900 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT combined with FIB
Number of subjects: 3
Study 20972900 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT combined with SAA
Number of subjects: 3
Study 20972900 — intervention group
Group type: COMPARATOR
Intervention: MSCT combined with CRP, FIB, and SAA
Number of subjects: 3
Study 17950795 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 1380
Study 17242663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 17242663 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) without EPO
Number of subjects: 0
Study 17242663 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) with EPO
Number of subjects: 0
Study 17242663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide vs BSC
Number of subjects: 0
Study 15360893 — intervention group
Group type: EXPERIMENTAL
Intervention: KNAVE-II
Number of subjects: 0
Study 15360893 — intervention group
Group type: COMPARATOR
Intervention: Paper or ESS
Number of subjects: 0
Study 10804778 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (300 mmol sodium/d, HS)
Number of subjects: 47
Study 10804778 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (30 mmol sodium/d, LS)
Number of subjects: 47
Study 8634878 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride 50 mg
Number of subjects: 67
Study 8634878 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg + pseudoephedrine 60 mg (A + P)
Number of subjects: 67
Study 8634878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 1628531 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support group meetings (8 meetings)
Number of subjects: 204
Study 1628531 — intervention group
Group type: COMPARATOR
Intervention: Control group (intensive outpatient diabetes training program only)
Number of subjects: 204
Study 6378232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (100 mg/day)
Number of subjects: 60
Study 6378232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30898204 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (1%) gel for 12 weeks
Number of subjects: 151
Study 30898204 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 151
Study 29247029 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter-time application protocol (1 application lasting electric block time to effect plus 60- and 120-second freeze bonus)
Number of subjects: 140
Study 29247029 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (180-second cryoballoon applications per vein with a bonus freeze)
Number of subjects: 140
Study 29247029 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter-time application protocol
Number of subjects: 140
Study 29247029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 27128212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (0.1, 0.3, 1, 3, 10, 30, 60, and 100 mg)
Number of subjects: 95
Study 27128212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 22983456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 50
Study 22983456 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (0.3 mg/kg)
Number of subjects: 50
Study 22097138 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaozhong Zhitong mixture (50 ml every time, twice a day for 4 weeks)
Number of subjects: 154
Study 22097138 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg every time, twice a day)
Number of subjects: 154
Study 22097138 — intervention group
Group type: COMPARATOR
Intervention: Sham group (no preventing treatment)
Number of subjects: 154
Study 22097138 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris scoring, PAHSS, and IAHSS
Number of subjects: 154
Study 22097138 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal reactions
Number of subjects: 154
Study 19186712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with tropisetron (5 mg daily for 6 days)
Number of subjects: 66
Study 19186712 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture combined with tropisetron (5 mg daily for 6 days)
Number of subjects: 66
Study 16583282 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based teaching (MI simulation followed by RAD lecture)
Number of subjects: 38
Study 16583282 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction (RAD simulation followed by MI lecture)
Number of subjects: 38
Study 14521826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 53
Study 14521826 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 10897186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination package with implementation manuals, staff training workshops, and follow-up consultation calls
Number of subjects: 74
Study 10897186 — intervention group
Group type: COMPARATOR
Intervention: Dissemination package with implementation manuals and staff training workshops
Number of subjects: 74